Enrolling

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

J3M-OX-JZQA -

The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment.

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Lung Cancer, Advanced Solid Tumors
What the trial is testing?
LY3537982, pembrolizumab, cetuximab, pemetrexed, cisplatin, carboplatin
Could I receive a Placebo?
No
Enrollment Goal
550
Trial Dates
Jul 19, 2021 - Jun 2026
How long will I be in the trial?
The study will last up to approximately 4 years
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Have a cancer tumor, with a change in the KRAS G12C gene, that is advanced and/or has spread to another part of the body

  • Be well enough to walk and do light work

  • Have adequate organ function and blood counts, as measured by blood tests

  • Have stopped all cancer treatment and have recovered from the major side effects

  • Be able to swallow capsules and/or tablets

Participants Must Not:

  • Have cancer that can be cured with treatments that target a specific part of the body (like surgery or radiation)

  • Have active infection or a serious medical condition (other than this cancer)

  • Have had another type of cancer within the last three years

  • Have cancer that has spread to the brain or spinal cord and is causing symptoms except for one part of the study

  • Have already had treatment with a drug that works in the same way as this study drug, except for certain patients with lung cancer

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources